Protecting Against Uveitis in Axial Spondyloarthritis (AxSpA)
Apr 30, 2024
auto_awesome
Dr. Katie Bechman discusses protecting against Uveitis in AxSpA patients through her research findings. Topics include systematic review on treatment options, managing Uveitis, navigating manuscript writing during the pandemic, and career aspirations in rheumatology.
Research shows potential for protection against Uveitis in AxSpA patients with novel treatments.
Systematic reviews of treatments for AxSpA patients highlight effectiveness in reducing uveitis rates.
Deep dives
Evolution of Systematic Reviews in Clinical Practice
Systematic reviews have evolved to become more rigorous, enabling data mining from various clinical trials to enhance the understanding of patient outcomes. This podcast delves into a systematic review exploring the incidence of uveitis in axial spondyloarthritis patients treated with biologics or targeted synthetics.
Importance of Systemic Reviews in Research
Systemic reviews provide statistical power by synthesizing data across multiple trials, revealing patterns not apparent in individual studies. Rigorous methodology in these reviews has become crucial, emphasizing the need to register protocols early to enhance transparency and reduce unplanned duplication.
Findings on Uveitis Incidence and Treatment Efficacy
The findings revealed an incidence of 1 to 5 episodes of uveitis per 100 patient years in axial spondyloarthritis patients. Treatments like TNF monoclonal antibodies, jack inhibitors, and IL-17 agents showed effectiveness in reducing uveitis rates, guiding rheumatologists in treatment decisions for patients with inflammatory arthritis.